...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>BMC Pulmonary Medicine >Temporal echocardiographic assessment of pulmonary hypertension in idiopathic pulmonary fibrosis patients treated with nintedanib with or without oxygen therapy
【24h】

Temporal echocardiographic assessment of pulmonary hypertension in idiopathic pulmonary fibrosis patients treated with nintedanib with or without oxygen therapy

机译：时效超声心动图评估使用Nintedanib联合或不联合氧气治疗的特发性肺纤维化患者的肺动脉高压

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Nintedanib is an inhibitor of receptor tyrosine kinases, including vascular endothelial growth factor receptor, but its effects on pulmonary hypertension (PH) in idiopathic pulmonary fibrosis (IPF) patients with chronic hypoxia were unclear. This study included a nintedanib prospective study and historical control study. In the nintedanib prospective study, pulmonary artery systolic pressure (PASP) measured using transthoracic echocardiography was evaluated at six points during 48?weeks in 16 IPF patients in whom nintedanib was started. In the historical control study, adjusted annual change in PASP was compared between patients treated with (n?=?16) and without (n?=?15) nintedanib. In the nintedanib prospective study, the mean PASP at 48?weeks after starting nintedanib was significantly higher compared to that at baseline. When IPF patients were divided into two groups, IPF patients with or without long-term oxygen treatment (LTOT), mean PASP at 48?weeks was significantly higher than that at baseline only in IPF patients receiving LTOT (P?=?0.001). In the historical control study, adjusted annual change in PASP in IPF patients treated with nintedanib was significantly lower than that in patients treated with no antifibrotic agents when considering patients without LTOT (0.26?mmHg vs 7.05?mmHg; P?=?0.011). We found differential effects of nintedanib on PH between IPF patients with or without LTOT. Nintedanib may have a disadvantageous effect on PH in IPF patients with LTOT. Conversely, nintedanib treatment may be beneficial to PH in IPF patients without LTOT.
机译：Nintedanib是一种受体酪氨酸激酶的抑制剂，包括血管内皮生长因子受体，但对于慢性低氧的特发性肺纤维化（IPF）患者，其对肺动脉高压（PH）的影响尚不清楚。这项研究包括nintedanib前瞻性研究和历史对照研究。在nintedanib前瞻性研究中，对16例开始使用nintedanib的IPF患者，在48周内通过经胸超声心动图测得的肺动脉收缩压（PASP）进行了评估。在历史对照研究中，比较了接受nintedanib（n？=？16）和未接受（n？=？15）治疗的患者的PASP调整后年度变化。在nintedanib前瞻性研究中，开始nintedanib后48周的平均PASP显着高于基线时。将IPF患者分为两组，即接受或不接受长期氧气治疗（LTOT）的IPF患者，在48周时的平均PASP仅比接受LTOT的IPF患者的基线时高（P？= 0.001）。在历史对照研究中，考虑到没有LTOT的患者时，用nintedanib治疗的IPF患者的PASP调整后的年变化显着低于未使用抗纤维化药物治疗的患者（0.26？mmHg vs 7.05？mmHg; P？=？0.011）。我们发现，在有或没有LTOT的IPF患者中，nintedanib对PH的不同影响。 Nintedanib可能对IPOT LTOT患者的PH有不利影响。相反，在没有LTOT的IPF患者中，nintedanib治疗可能对PH有益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号